Newsroom - University of Sydney
newsroomusyd.bsky.social
Welcome to the University of Sydney's Newsroom. This media-friendly channel highlights the global work of our researchers, with new ideas and collaborative breakthroughs tailored for busy journalists by our Media Office team: https://bit.ly/4ou82jQ
👤 Joined on 09 September 2025
82
Followers
153
Following
31
Total Posts
📜 Kullanıcı Geçmişi
- 09 Eyl 2025, 06:44
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@newsroomusyd.bsky.social
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
Words from the last 30 minutes 🧭: 1. Trump 2. Christmas 3. Hegseth ⬆ 4. December 5. Fog 6. Pardons 7. #TrêsGraças 🆕 8. Tuesday ⬆ 9. FBI 🆕 10. Kash 🆕 Ad: @terraprotege.bsky.social.
Show Post
Alector has announced results from its Phase 3 trial of latozinemab (AL001) for FTD-GRN. While the study did not meet its goals, it offers insight that will guide future FTD research. Thank you to all who participated and continue to advance FTD research. Learn more: ftdregistry.org/press/alecto...
Show Post
Just over two weeks until our Better Conversations course in Sydney & three weeks until Perth. Shouting out to all Speech Pathologists in NSW and WA- we’d love to see you. And there are places still available!!! Sign up: www.ucl.ac.uk/brain-scienc...
Show Post
Join ISFTD's Webinar on AI in FTD: From Neuropathology to MRI to Clinic Wednesday, 29th October, 2025 at 11:00 AM EST. www.isftd.org/events/webin... #endFTD #ISFTD
Show Post
Results from Alector Therapeutics’ Phase 3 trial for Latozinemab (AL001), designed for people with FTD caused by GRN variants, have raised important questions for many. Join us on Nov. 6 for a live discussion about what these results mean and what’s next for FTD research: https://bit.ly/3Lw3Sco
Show Post